{
    "document_id": 14917,
    "page": 66,
    "width_pt": 612,
    "height_pt": 792,
    "rotation": 0,
    "pipeline_version": "paddleocr-vl-1.6+paul-48",
    "engine": "paddleocr_vl",
    "source_run_id": 15031,
    "item_count": 13,
    "counts_by_type": {
        "heading": 3,
        "text": 10
    },
    "build_ms": 2,
    "items": [
        {
            "id": "p66.1",
            "order": 1,
            "type": "text",
            "bbox": {
                "l": 68.88,
                "t": 719.76,
                "r": 542.16,
                "b": 690.24
            },
            "text": "participants; and a summary of recent literature, findings, or other relevant information, if any, that may have an impact on the research and risks for human subjects."
        },
        {
            "id": "p66.2",
            "order": 2,
            "type": "text",
            "bbox": {
                "l": 68.4,
                "t": 678.24,
                "r": 542.64,
                "b": 593.28
            },
            "text": "As with the original application for IRB approval, all applicable supporting documents must be included with the application, such as recruitment materials, informed consent documents, and any test or survey instruments to be used. Application forms will have further instructions as to the additional documents required for review. In addition, researchers must ensure that the OSP staff has on file certificates demonstrating that the researcher and their assistants completed CITI training within the last three years."
        },
        {
            "id": "p66.3",
            "order": 3,
            "type": "text",
            "bbox": {
                "l": 68.88,
                "t": 581.52,
                "r": 541.92,
                "b": 524.64
            },
            "text": "After receiving the complete application package, OSP staff will conduct a preliminary screening of the application, and once the screening has been completed and any issues with the screening have been addressed, OSP staff will provide the application package to the IRB at least one week before the full Board meeting."
        },
        {
            "id": "p66.4",
            "order": 4,
            "type": "text",
            "bbox": {
                "l": 68.64,
                "t": 513.36,
                "r": 543.12,
                "b": 469.68
            },
            "text": "All procedures outlined for the initial review of research by the full Board will be followed in the continuing review of research by the full Board, including the use of a primary/secondary reviewer system and a checklist for reviewers."
        },
        {
            "id": "p66.5",
            "order": 5,
            "type": "heading",
            "bbox": {
                "l": 70.32,
                "t": 457.44,
                "r": 194.16,
                "b": 442.56
            },
            "text": "10.2 Review Timeline",
            "attrs": {
                "block_label": "paragraph_title"
            },
            "level": 3
        },
        {
            "id": "p66.6",
            "order": 6,
            "type": "text",
            "bbox": {
                "l": 68.64,
                "t": 429.84,
                "r": 542.88,
                "b": 372.96
            },
            "text": "Applications for full continuing review should be submitted to the OSP approximately two months before the approval end date to allow ample time for processing, review, and approval. Applications for expedited continuing reviews should be submitted at least 30 calendar days prior to the approval end date."
        },
        {
            "id": "p66.7",
            "order": 7,
            "type": "text",
            "bbox": {
                "l": 68.64,
                "t": 360.72,
                "r": 542.88,
                "b": 318
            },
            "text": "Applications that are not processed and approved before the approval expiration date will result in the expiration of the protocol's approval and will require that researchers delay further research involving human subjects until approval is renewed."
        },
        {
            "id": "p66.8",
            "order": 8,
            "type": "heading",
            "bbox": {
                "l": 69.84,
                "t": 305.76,
                "r": 318.72,
                "b": 290.4
            },
            "text": "10.3 Considerations for Continuing Review",
            "attrs": {
                "block_label": "paragraph_title"
            },
            "level": 3
        },
        {
            "id": "p66.9",
            "order": 9,
            "type": "text",
            "bbox": {
                "l": 68.88,
                "t": 277.92,
                "r": 541.68,
                "b": 249.12
            },
            "text": "For continuing review, the IRB must have the same considerations and use the same criteria to approve the continuation of a protocol as in the initial review of research."
        },
        {
            "id": "p66.10",
            "order": 10,
            "type": "text",
            "bbox": {
                "l": 68.4,
                "t": 236.4,
                "r": 542.64,
                "b": 165.84
            },
            "text": "At the same time, when conducting continuing review, the IRB needs to determine whether any new information has emerged either from the research itself or from other sources that could affect the IRB's approval of the continuation of research, particularly with respect to risk to subjects. In addition to the considerations outlined in section 7.2, the IRB at the time of continuing review will consider the following:"
        },
        {
            "id": "p66.11",
            "order": 11,
            "type": "heading",
            "bbox": {
                "l": 70.32,
                "t": 153.6,
                "r": 248.16,
                "b": 138.72
            },
            "text": "Risk Assessment and Monitoring",
            "attrs": {
                "block_label": "paragraph_title"
            },
            "level": 3
        },
        {
            "id": "p66.12",
            "order": 12,
            "type": "text",
            "bbox": {
                "l": 69.12,
                "t": 126.24,
                "r": 542.88,
                "b": 83.04
            },
            "text": "The IRB's continuing review should consider relevant information received from the investigator, any monitoring entity (such as the research sponsor, a coordinating or statistical center, a data and safety monitoring board, or a data monitoring committee), or"
        },
        {
            "id": "p66.13",
            "order": 13,
            "type": "text",
            "bbox": {
                "l": 526.56,
                "t": 72.48,
                "r": 541.44,
                "b": 61.68
            },
            "text": "34",
            "attrs": {
                "block_label": "number"
            }
        }
    ],
    "excluded_furniture": {
        "first": [],
        "last": []
    }
}